Onco360, a national independent specialty pharmacy, was selected by SpringWorks Therapeutics as a national pharmacy partner for GOMEKLI (mirdametinib) on February 17, 2025. This partnership is crucial for the commercial distribution of the recently FDA-approved therapy.
The collaboration ensures that GOMEKLI, approved for adult and pediatric patients with NF1-PN, will be accessible to patients across the United States. Onco360's expertise in rare disease therapies supports the effective launch and patient support for GOMEKLI.
This strategic partnership facilitates the delivery of GOMEKLI to patients, addressing the specialized needs associated with rare disease treatments. It marks a significant step in SpringWorks' efforts to commercialize its second approved medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.